8-K: IDEAYA Biosciences Appoints Joshua Bleharski as New Chief Financial Officer
Management Change
IDEAYA Biosciences, Inc. announced the appointment of Joshua Bleharski, Ph.D., as its new Chief Financial Officer and Principal Financial Officer, effective June 26, 2025.
Summary
- IDEAYA Biosciences, Inc. (the "Company") appointed Joshua Bleharski, Ph.D., as Chief Financial Officer and Principal Financial Officer.
- The appointment was made by the Company's Board of Directors at a meeting held on June 26, 2025.
- Dr. Bleharski will serve as Principal Financial Officer under Section 16(a)-1(f) of the Securities Exchange Act of 1934, as amended.
Sentiment
Score: 5
Explanation: The document reports a standard executive appointment, which is a neutral event without additional context on the previous CFO's departure or the new CFO's specific mandate.
Industry Context
This is a routine corporate governance update for a biotechnology company, reflecting a standard change in executive leadership. Such appointments are common in the industry as companies evolve or leadership roles transition.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer | Not specified | Joshua Bleharski, Ph.D. | 2025-06-26 | Appointment by Board of Directors |
| Principal Financial Officer | Not specified | Joshua Bleharski, Ph.D. | 2025-06-26 | Appointment by Board of Directors under Section 16(a)-1(f) of the Securities Exchange Act of 1934 |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Executive Appointment | Appointment of Joshua Bleharski, Ph.D. as Chief Financial Officer and Principal Financial Officer. | 2025-06-26 | Strengthens the executive leadership team with a new financial officer, a standard corporate governance practice. |
Stakeholder Impact
- Shareholders: Standard executive appointment, generally neutral unless specific strategic shifts are implied.
- Employees: Potential for new financial leadership and strategic direction.
- Management: Integration of a new key executive into the leadership team.
Key Dates
| Date | Description |
|---|---|
| 2025-06-26 | Date of earliest event reported; Board of Directors meeting where Joshua Bleharski was appointed CFO and Principal Financial Officer. |
| 2025-06-27 | Date the Form 8-K was signed by Yujiro Hata, President and Chief Executive Officer. |
Keywords
IDEAYA Biosciences, IDYA, Chief Financial Officer, CFO, Principal Financial Officer, Joshua Bleharski, Management Appointment, Corporate Governance, SEC Filing, 8-K
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.